Boston Scientific closed the acquisition of Vertiflex, developer of the Superion® Indirect Decompression System to treat lumbar spinal stenosis.
Superion is the only commercially available, minimally invasive interspinous spacer with FDA Premarket Approval. It complements Boston Scientific’s pain management portfolio, which includes spinal cord stimulation and radiofrequency ablation.
The transaction comprises USD $465MM in upfront cash with additional payments contingent on commercial milestones for the next three years.
Boston Scientific closed the acquisition of Vertiflex, developer of the Superion® Indirect Decompression System to treat lumbar spinal stenosis.
Superion is the only commercially available, minimally invasive interspinous spacer with FDA Premarket Approval. It complements Boston Scientific's pain management portfolio, which includes spinal...
Boston Scientific closed the acquisition of Vertiflex, developer of the Superion® Indirect Decompression System to treat lumbar spinal stenosis.
Superion is the only commercially available, minimally invasive interspinous spacer with FDA Premarket Approval. It complements Boston Scientific’s pain management portfolio, which includes spinal cord stimulation and radiofrequency ablation.
The transaction comprises USD $465MM in upfront cash with additional payments contingent on commercial milestones for the next three years.
Copy to clipboard 
